Establishment of CD8+ T Cell Thymic Central Tolerance to Tissue-Restricted Antigen Requires PD-1.


Journal

Journal of immunology (Baltimore, Md. : 1950)
ISSN: 1550-6606
Titre abrégé: J Immunol
Pays: United States
ID NLM: 2985117R

Informations de publication

Date de publication:
20 Nov 2023
Historique:
received: 21 10 2022
accepted: 02 11 2023
medline: 20 11 2023
pubmed: 20 11 2023
entrez: 20 11 2023
Statut: aheadofprint

Résumé

Highly self-reactive T cells are censored from the repertoire by both central and peripheral tolerance mechanisms upon receipt of high-affinity TCR signals. Clonal deletion is considered a major driver of central tolerance; however, other mechanisms such as induction of regulatory T cells and functional impairment have been described. An understanding of the interplay between these different central tolerance mechanisms is still lacking. We previously showed that impaired clonal deletion to a model tissue-restricted Ag did not compromise tolerance. In this study, we determined that murine T cells that failed clonal deletion were rendered functionally impaired in the thymus. Programmed cell death protein 1 (PD-1) was induced in the thymus and was required to establish cell-intrinsic tolerance to tissue-restricted Ag in CD8+ thymocytes independently of clonal deletion. In bone marrow chimeras, tolerance was not observed in PD-L1-deficient recipients, but tolerance was largely maintained following adoptive transfer of tolerant thymocytes or T cells to PD-L1-deficient recipients. However, CRISPR-mediated ablation of PD-1 in tolerant T cells resulted in broken tolerance, suggesting different PD-1 signaling requirements for establishing versus maintaining tolerance. Finally, we showed that chronic exposure to high-affinity Ag supported the long-term maintenance of tolerance. Taken together, our study identifies a critical role for PD-1 in establishing central tolerance in autoreactive T cells that escape clonal deletion. It also sheds light on potential mechanisms of action of anti-PD-1 pathway immune checkpoint blockade and the development of immune-related adverse events.

Identifiants

pubmed: 37982696
pii: 266464
doi: 10.4049/jimmunol.2200775
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Gouvernement du Canada | Canadian Institutes of Health Research (IRSC)
ID : PS 156104

Informations de copyright

Copyright © 2023 by The American Association of Immunologists, Inc.

Auteurs

Julia F May (JF)

Department of Medical Microbiology and Immunology, University of Alberta, Edmonton, Alberta, Canada.

Rees G Kelly (RG)

Department of Medical Microbiology and Immunology, University of Alberta, Edmonton, Alberta, Canada.

Alexander Y W Suen (AYW)

Department of Medical Microbiology and Immunology, University of Alberta, Edmonton, Alberta, Canada.

Jeongbee Kim (J)

Department of Surgery, University of Alberta, Edmonton, Alberta, Canada.

Jeongwoo Kim (J)

Department of Surgery, University of Alberta, Edmonton, Alberta, Canada.

Colin C Anderson (CC)

Department of Medical Microbiology and Immunology, University of Alberta, Edmonton, Alberta, Canada.
Department of Surgery, University of Alberta, Edmonton, Alberta, Canada.

Gina R Rayat (GR)

Department of Surgery, University of Alberta, Edmonton, Alberta, Canada.
Ray Rajotte Surgical-Medical Research Institute, AB Diabetes and Transplant Institutes, University of Alberta, Edmonton, Alberta, Canada.

Troy A Baldwin (TA)

Department of Medical Microbiology and Immunology, University of Alberta, Edmonton, Alberta, Canada.

Classifications MeSH